Atmeksi® (methocarbamol) – New drug approval
July 30, 2025 - The FDA approved Rosemont Pharmaceuticals’ Atmeksi (methocarbamol) oral suspension, as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.